HTS Platform to Advance Molecular Glue Discovery

Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues offer a promising solution by inducing novel protein-protein interactions that enable degradation, stabilization, or functional modulation of previously undruggable targets.

However, molecular glue drug discovery is hindered by the lack of a rational design framework that can predict ternary complex stability. Rational design of molecular glues is challenging because it requires creating a molecule capable of bridging two proteins that may have no natural affinity for each other.

At SLAS 2026, WuXi Biology and Testing presented a poster highlighting our comprehensive hit-finding capabilities. The authors demonstrate how our HTS 2.0 platform provides an integrated solution to quickly validate molecular glue hits, enabling a seamless ‘design-make-test’ cycle using “direct-to-biology” technology to profile these hits and accelerate molecular glue discovery.